Etkin Amit 4

What Happened
Etkin Amit, President and CEO (and director) of Alto Neuroscience (ANRO), was granted a derivative equity award covering 306,000 shares on February 11, 2026. The Form 4 reports an acquisition-type derivative with a reported price of $0.00 (no cash paid at grant). This was a grant/award — not a stock purchase or sale — and did not generate proceeds or an immediate change in market-held shares.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (filed within the usual two-business-day window).
• Award type on Form 4: "Grant, award or other acquisition (A)" recorded as a derivative; reported price = $0.00.
• Number of shares/units: 306,000 underlying shares.
• Vesting (per footnote F1): 25% of the shares vest on February 11, 2027, then 1/48th of the shares vest monthly thereafter, subject to continuous service.
• Shares beneficially owned after the transaction: not specified on the filing.
• No sale or exercise reported — this is a compensation award, not a cash transaction.

Context

• This filing documents a compensation grant (an option-like award) rather than insider buying or selling. Such grants are common for executives and reflect compensation arrangements rather than a direct market signal.
• Because the award vests over time and requires continued service, the shares are not immediately tradable; future filings (Form 4s) will disclose any exercises or sales once vesting/transactions occur.